Shares of Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) have earned a consensus rating of “Hold” from the twenty-two brokerages that are covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have assigned a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $71.05.
A number of brokerages have recently weighed in on TEM. TD Cowen restated a “buy” rating on shares of Tempus AI in a research note on Wednesday, July 15th. Stifel Nicolaus reduced their target price on Tempus AI from $60.00 to $50.00 and set a “hold” rating for the company in a report on Monday, August 3rd. BTIG Research increased their price target on Tempus AI from $70.00 to $80.00 and gave the company a “buy” rating in a research report on Thursday, August 20th. The Goldman Sachs Group began coverage on Tempus AI in a report on Monday, September 21st. They set a “neutral” rating and a $75.00 price target on the stock. Finally, Raymond James Financial set a $80.00 price objective on Tempus AI in a research report on Wednesday, September 2nd.
Get Our Latest Stock Report on Tempus AI
Insider Activity
In other news, CEO Ryan Fukushima sold 700 shares of Tempus AI stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $70.00, for a total transaction of $49,000.00. Following the sale, the chief executive officer directly owned 15,874 shares in the company, valued at $1,111,180. The trade was a 4.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Eric P. Lefkofsky sold 250,000 shares of the business’s stock in a transaction dated Tuesday, September 22nd. The stock was sold at an average price of $77.47, for a total transaction of $19,367,500.00. Following the completion of the transaction, the chief executive officer directly owned 100,000 shares in the company, valued at $7,747,000. This trade represents a 71.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 1,280,965 shares of company stock worth $80,397,564. 24.26% of the stock is owned by insiders.
Hedge Funds Weigh In On Tempus AI
Several institutional investors have recently added to or reduced their stakes in the stock. EMC Capital Management bought a new position in Tempus AI during the second quarter valued at $29,000. Whittier Trust Co. increased its position in Tempus AI by 190.0% in the first quarter. Whittier Trust Co. now owns 870 shares of the company’s stock worth $41,000 after buying an additional 570 shares during the last quarter. Global Assets Advisory LLC purchased a new stake in Tempus AI in the first quarter worth $46,000. CoreCap Advisors LLC raised its stake in shares of Tempus AI by 293.4% in the second quarter. CoreCap Advisors LLC now owns 1,019 shares of the company’s stock valued at $59,000 after buying an additional 760 shares during the period. Finally, Eastern Bank bought a new stake in shares of Tempus AI in the third quarter valued at $69,000. Institutional investors own 24.22% of the company’s stock.
Tempus AI Price Performance
TEM opened at $70.93 on Monday. Tempus AI has a fifty-two week low of $40.77 and a fifty-two week high of $101.56. The firm has a market capitalization of $12.80 billion, a P/E ratio of -49.26 and a beta of 3.54. The company’s 50-day moving average is $66.02 and its 200 day moving average is $55.78. The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16.
Tempus AI (NASDAQ:TEM – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10. The business had revenue of $382.49 million during the quarter, compared to the consensus estimate of $379.69 million. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The firm’s quarterly revenue was up 21.6% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.22) EPS. Research analysts expect that Tempus AI will post -1.38 earnings per share for the current fiscal year.
Tempus AI Company Profile
Tempus AI, Inc is a technology company focused on applying artificial intelligence and data analytics to precision medicine. The company develops tools intended to help physicians make more informed treatment decisions by combining clinical information, molecular data and other health-related datasets.
Tempus provides genomic testing and diagnostic services, including sequencing and other molecular tests used primarily in oncology. Its platform also offers data and software solutions designed to support clinical research, pharmaceutical development, patient identification for clinical trials and the development of personalized treatment strategies.
Founded in 2015, Tempus is headquartered in Chicago and primarily serves healthcare providers, researchers and life sciences companies.
Featured Stories
- Five stocks we like better than Tempus AI
- 3 Stocks Chopped in Half: Why These Drops May Be Structural, Not a Dip
- Home Depot and Lowe’s Hit 52-Week Lows—But Analysts Aren’t Giving Up
- Utilities Are Bouncing Back—These 2 Giants Could Signal the Next Big Sector Rally
- Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes Next
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Tempus AI Right Now?
Before you consider Tempus AI, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Tempus AI wasn’t on the list.
While Tempus AI currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don’t have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
